X

Blood Advances

Blood Advances
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia and Richter’s Transformation

RIC-HSCT yields favorable outcomes for patients with high-risk CLL-RT, especially when performed in early remission.

Blood Advances
07/23/2021
Phase 3 Randomized Trial of Chemotherapy With or Without Oblimersen in Older AML Patients

Oblimersen (G3139) can be safely added to conventional chemotherapy for older patients with AML.

Blood Advances
07/12/2021
Polatuzumab Vedotin as a Salvage and Bridging Treatment in Relapsed or Refractory Large B-Cell Lymphomas

Pola is an effective treatment in heavily pretreated patients with r/r LBCL, but long-term remissions are rare.

Blood Advances
07/01/2021
Intratumoral T Cells Have a Differential Impact on FDG-PET Parameters in Follicular Lymphoma

Pretherapy TMTV is reflective of the FL tumor cell burden within malignant nodes.

Blood Advances
06/22/2021
Posttransplant Cyclophosphamide as GVHD Prophylaxis for Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Transplant

Highly promising OS and GRFS rates of 87% and 68%, respectively, were achieved after MMUD-HCT with PTCy.

Blood Advances
06/22/2021
Toxicities of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Older Patients With Lymphoma

Cardiovascular toxicities are higher in older patients, but nonrelapse mortality at 100 days and 1 year is comparable to younger patients.

Blood Advances
06/21/2021
Effect of DNMT3A Variant Allele Frequency and Double Mutation on Clinicopathologic Features of Patients With de novo AML

The clinicopathologic features of DNMT3A-mutated de novo AML, and the significance of variant type, variant allele frequency, and multiple concomitant DNMT3A mutations, remain poorly defined.

Blood Advances
06/08/2021
Clinical Implications of Sequential MRD Monitoring by NGS at 2 Time Points After Chemotherapy in Patients With AML

In this study, investigators aim to examine the clinical significance of NGS MRD at 2 different time points. 

Blood Advances
05/17/2021
SETBP1 Overexpression Acts in the Place of Class-Defining Mutations to Drive FLT3-ITD–Mutant AML

SETBP1 overexpression activates a HOXA signature and collaborates with FLT3-ITD to drive AML in the absence of class-defining mutations.

Blood Advances
05/06/2021
Potent Preclinical Activity of HexaBody-DR5/DR5 in Relapsed and/or Refractory Multiple Myeloma

This study explores the preclinical activity of HexaBody-DR5/DR5 in multiple myeloma, because MM cells are known to express DR5.

Blood Advances
04/22/2021
Subscribe to Blood Advances

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834